{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"26"}]}],"title":"Hypophosphatemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"20"}]}],"title":"Phosphorus not reported at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"9"}]}],"title":"Hypocalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"}]}],"title":"Calcium not reported at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"title":"Elevated ALT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}],"title":"ALT not reported at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"title":"Elevated AST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"title":"AST not reported at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}],"title":"Elevated Bilirubin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"title":"Bilirubin not reported at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"title":"Elevated Serum Creatinine"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Serum Creatinine not reported at baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"304"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"Laboratory abnormalities were graded according to the NCI CTC version 3.0. Grade 3 and 4 criteria were defined as follows: Upper limit of normal (ULN). Alanine transaminase (ALT) Grade (Gr) 3: \\>5.0 to 20.0\\*ULN; Gr 4: \\>20.0\\*ULN. Aspartate aminotransferase (AST) Gr 3: \\>5.0 to 20.0\\*ULN; Gr 4: \\>20.0\\*ULN. Total bilirubin Gr 3: \\>3.0 to 10..0\\*ULN; Gr 4: \\>10.0.0\\*ULN. Serum creatinine (H) Gr 3: \\>3.0 to 6.0\\*ULN; Gr 4: \\>6.0\\*ULN. Calcium (L) Gr3: 6.0-7.0; Gr 4: \\<6.0 mg/dL; Phosphorus (L): Gr 3: \\<2.0 - 1.0 mg/dL , Gr 4: \\<1.0 mg/dL. Non-hematologic laboratory results were not collected beyond Year 2. Baseline values were obtained within 2 weeks prior to randomization.","groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"OG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant..","id":"OG001","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study drug were analyzed. Participants were analyzed based on the treatment they actually received, not what they were randomized to receive. Participants who did not have a parameter reported at baseline are indicated.","reportingStatus":"POSTED","timeFrame":"Baseline to Year 2","title":"Number of Participants With Normal Baseline Versus Worst Grade 3/4 Biochemistry Laboratory Abnormalities up to Year 2 in Treated Participants","type":"SECONDARY","unitOfMeasure":"participants"}